Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) Aims for Rapid Delivery of Cancer, Skin, Female Sexual Dysfunction Therapies
- Pivot developing nutraceutical and pharmaceutical therapies based on cannabis derivatives
- Female sexual dysfunction market expected to exceed booming male products market
- Skin and oral delivery of Pivot products driven by innovative technologies
The advent of modern licensing controls for over-the-counter medications in Canada nearly 15 years ago paved the way for people to pursue health options ranging from traditional Chinese medicines to manufactured vitamins with greater freedom. Caught up in the current were a number of cannabis-based therapies taking advantage of the growing attention paid to the plant’s medicinal properties. Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) is one of those companies, using the path to retail enabled by the Natural and Non-prescription Health Products Directorate in its effort to provide consumers with topical treatments for women’s sexual dysfunction and psoriasis, and an oral product for cancer supportive care, while, in the United States, its cannabinoid products anticipate wide availability through a state-by-state regulatory process.
Pivot Pharmaceuticals is an emerging biopharmaceutical company intent on using novel drug-delivery technologies to commercialize a variety of therapeutic pharmaceuticals and nutraceuticals, beginning with the three skin, cancer and sexual dysfunction products in development through agreements with Solmic GmbH (a privately / held German company) leveraging Pivot’s BiPhasix technology. Pivot’s technologies have shown a capacity for enhancing the bioavailability of the health products they carry while maintaining product stability (http://nnw.fm/wn10J).
The success of erectile dysfunction product manufacture for men revealed a tableau of opportunities for pharmaceuticals treating time-of-life maladies that now are extending to women’s health as well. Men’s products have resulted in a $3 billion-plus market, but researchers estimate a larger potential market exists for women (http://nnw.fm/dbA3W) with the likelihood of a $7.7 billion combined market by 2019 (http://nnw.fm/d9uHZ). Pivot’s cannabidiol (CBD) product targets a decline in sexual desire and response in perimenopausal, menopausal and post-menopausal women through an applicable cream.
Cancer patients troubled by nausea, vomiting, mucositis, neutropenia and anemia — a reported 70 to 80 percent of those undergoing chemotherapy (http://nnw.fm/8CzeJ) — are already finding Pivot’s therapeutic natural product treatment in Europe. Grand View Research’s forecasts anticipate a $29.87 billion cancer supportive care products market by 2021, and preclinical research into the anti-inflammatory benefits of cannabis are driving product development for treating dry, itchy skin ailments such as psoriasis and eczema. Statista predicts that the global skin disease care market will grow to $20.4 billion by 2020, with $8.6 billion of that coming from the United States (http://nnw.fm/w1iqV).
Pivot anticipates that the natural health product regulatory pipeline, such as that envisioned by Canada’s NNHPD, will help get its products into consumers’ hands more quickly than extended pharmaceutical trials and ,in so doing, will ultimately accomplish the products’ purpose of providing relief to the masses. Pivot’s medical cannabis product division, Pivot Green Stream Health Solutions (PGS), is responsible for taking products from research through commercialization, both in the nutraceutical and the pharmaceutical pipelines, involving not only CBD but also products derived from its more regulated tetrahydrocannabinol (THC) sibling. Other products anticipated for development will target pain, inflammation and eye disease.
For more information, visit the company’s website at www.PivotPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Pivot developing nutraceutical and pharmaceutical therapies based on cannabis derivatives
- Female sexual dysfunction market expected to exceed booming male products market
- Skin and oral delivery of Pivot products driven by innovative technologies
The advent of modern licensing controls for over-the-counter medications in Canada nearly 15 years ago paved the way for people to pursue health options ranging from traditional Chinese medicines to manufactured vitamins with greater freedom. Caught up in the current were a number of cannabis-based therapies taking advantage of the growing attention paid to the plant’s medicinal properties. Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) is one of those companies, using the path to retail enabled by the Natural and Non-prescription Health Products Directorate in its effort to provide consumers with topical treatments for women’s sexual dysfunction and psoriasis, and an oral product for cancer supportive care, while, in the United States, its cannabinoid products anticipate wide availability through a state-by-state regulatory process.
Pivot Pharmaceuticals is an emerging biopharmaceutical company intent on using novel drug-delivery technologies to commercialize a variety of therapeutic pharmaceuticals and nutraceuticals, beginning with the three skin, cancer and sexual dysfunction products in development through agreements with Solmic GmbH (a privately / held German company) leveraging Pivot’s BiPhasix technology. Pivot’s technologies have shown a capacity for enhancing the bioavailability of the health products they carry while maintaining product stability (http://nnw.fm/wn10J).
The success of erectile dysfunction product manufacture for men revealed a tableau of opportunities for pharmaceuticals treating time-of-life maladies that now are extending to women’s health as well. Men’s products have resulted in a $3 billion-plus market, but researchers estimate a larger potential market exists for women (http://nnw.fm/dbA3W) with the likelihood of a $7.7 billion combined market by 2019 (http://nnw.fm/d9uHZ). Pivot’s cannabidiol (CBD) product targets a decline in sexual desire and response in perimenopausal, menopausal and post-menopausal women through an applicable cream.
Cancer patients troubled by nausea, vomiting, mucositis, neutropenia and anemia — a reported 70 to 80 percent of those undergoing chemotherapy (http://nnw.fm/8CzeJ) — are already finding Pivot’s therapeutic natural product treatment in Europe. Grand View Research’s forecasts anticipate a $29.87 billion cancer supportive care products market by 2021, and preclinical research into the anti-inflammatory benefits of cannabis are driving product development for treating dry, itchy skin ailments such as psoriasis and eczema. Statista predicts that the global skin disease care market will grow to $20.4 billion by 2020, with $8.6 billion of that coming from the United States (http://nnw.fm/w1iqV).
Pivot anticipates that the natural health product regulatory pipeline, such as that envisioned by Canada’s NNHPD, will help get its products into consumers’ hands more quickly than extended pharmaceutical trials and ,in so doing, will ultimately accomplish the products’ purpose of providing relief to the masses. Pivot’s medical cannabis product division, Pivot Green Stream Health Solutions (PGS), is responsible for taking products from research through commercialization, both in the nutraceutical and the pharmaceutical pipelines, involving not only CBD but also products derived from its more regulated tetrahydrocannabinol (THC) sibling. Other products anticipated for development will target pain, inflammation and eye disease.
For more information, visit the company’s website at www.PivotPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
